BRIEF published on 06/20/2024 at 13:05, 5 months 1 day ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
PRESS RELEASE published on 06/20/2024 at 13:00, 5 months 1 day ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 5 months 2 days ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
PRESS RELEASE published on 06/19/2024 at 13:00, 5 months 2 days ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 5 months 3 days ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
PRESS RELEASE published on 06/18/2024 at 13:00, 5 months 3 days ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
BRIEF published on 06/14/2024 at 22:50, 5 months 6 days ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase® Shareholders Theralase® Virtual Meeting AGSM Zoom Presentation
PRESS RELEASE published on 06/14/2024 at 22:45, 5 months 6 days ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders Annual General Meeting Shareholders Theralase Technologies Inc. AGSM Virtual Zoom Presentation
BRIEF published on 06/12/2024 at 13:05, 5 months 9 days ago Rutherrin® Increases Efficacy of Chemotherapy Cancer Treatment Chemotherapy Rutherrin® Multidrug Resistance Theralase® Technologies
PRESS RELEASE published on 06/12/2024 at 13:00, 5 months 9 days ago Rutherrin(R) Increases Efficacy of Chemotherapy Theralase Technologies announces preclinical success of Rutherrin® in enhancing chemotherapy efficacy and reducing multidrug resistance in cancer cells Cancer Treatment Theralase Technologies Rutherrin® Multidrug Resistance Chemotherapy Efficacy
Published on 11/21/2024 at 16:30, 33 minutes ago The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 2 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 3 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 1 hour 3 minutes ago Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 1 hour 3 minutes ago Isaac Ullatil Joins Wellstack Board of Directors
Published on 11/21/2024 at 15:41, 1 hour 21 minutes ago Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 40 minutes ago Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 41 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 06:58, 10 hours 5 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 21 hours 43 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 23 hours 18 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 23 hours 18 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 9 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
